HPLC法测定水合羟基化头孢克洛杂质研究

摘要：目的 建立HPLC法测定水合羟基化头孢克洛杂质方法。方法 采用C18(4.6 mm×250 mm,5 μm)色谱柱;流动相A为0.78%磷酸二氢钠溶液(取磷酸二氢钠7.8 g,加水溶解并稀释至1000 mL,用磷酸调pH至4.0),流动相B为0.78%磷酸二氢钠溶液(pH 4.0)-乙腈(55:45);流速1.2 mL/min;检测波长220 nm;柱温25℃。结果 水合羟基化头孢克洛杂质在9.108×10-4~3.4×10-2 mg/mL 范围内线性关系良好(r=1.0000),平均回收率为104.03%,RSD为0.82%(n=9),定量限为17.721 ng。在回收率试验中加入的水合羟基化头孢克洛杂质,采用外标法和加校正因子的主成分自身对照法的结果一致,该杂质的相对保留时间约为1.11,校正因子为1.02。结论 该方法操作简便、准确度高、重现性好,可以采用不加校正因子的主成分自身对照法对水合羟基化头孢克洛杂质进行检测。     

复方头孢克洛片制备及稳定性考察

目的 研究复方头孢克洛片的处方和制备工艺.方法 配制复方头孢克洛片,并制定质量标准,采用高效液相色谱法测定含量及进行稳定性考察.结果 以该处方工艺制成的片剂,质量可控,稳定性较好.结论 本品处方工艺成熟,质量可控,稳定性较好.     

Antimicrobial resistance in Gram-negative bacteria from Intensive Care Units and Urology Services. A nationwide study in The Netherlands 1995-2000

A nationwide 6-year surveillance of resistance in Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and Pseudomonas aeruginosa from clinical specimens of patients from ten Intensive Care Units and ten Urology Services was started in 1995. MICs of amoxycillin, amoxycillin/clavulanate, trimethoprim, cotrimoxazole, norfloxacin, ciprofloxacin, cefaclor, ceftazidime, imipenem and gentamicin were determined by broth microdilution. Intensive Care Units had higher resistance levels of amoxycillin/clavulanate, cefaclor and ceftazidime (P<0.005) and lower resistance levels of nitrofurantoin, trimethoprim, cotrimoxazole and quinolones (P<0.01) than Urology Services. Changes in MIC distributions in time and development of resistant clusters were observed for nitrofurantoin (E. coli), amoxycillin (E. coli, P. mirabilis), amoxycillin/clavulanate (E. coli) and for quinolones (E. coli). The overall resistance level of ceftazidime and gentamicin was <5%, but this fluctuated with the appearance and disappearance of resistant clones in some Intensive Care Units. Quinolone resistance among P. aeruginosa from Intensive Care Units fluctuated between 7 and 14%.     

头孢克罗胶囊人体相对生物利用度研究

目的:评价头孢克罗胶囊2种制剂的生物等效性。方法:采用高效液相色谱法测定受试者随机交叉单剂量口服头孢克罗胶囊受试制剂或参比制剂后不同时刻的血药浓度。Cmax、tmax采用实测值,AUC用梯形面积法计算,用双单侧t检验评价2种制剂的生物等效性。结果:受试制剂与参比制剂的AUC0～4分别为(13.44±3.06)、(14.19±3.28)(μg·h)/ml;AUC0～∞分别为(13.80±3.08)、(14.62±3.33)(μg·h)/ml;Cmax分别为(11.65±2.39)、(12.37±2.41)μg/ml;tmax分别为(0.57±0.24)h、(0.66±0.19)h;受试制剂的相对生物利用度为(95.62±13.51)%。结论:2种制剂具有生物等效性。